Labomed S.A is proud to announce the successful Pivotal BE outcome of Lisdexamfetamine Oral Solution 10mg/ml that has been co-sponsored & developed with Adalvo & Pharma-Data at our premises. We are moving ahead with the regulatory EU submission & US tech. transfer, whereby DCP slots have already been granted.
This added value version of Lisdexamfetamine comes in the form of a taste-masked, ready-to-use oral solution. Our product is a child-friendly, re-purposed version of Elvanse®, a CNS drug that is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Leveraging on Lisdexamfetamine and applying for a European and US Patent, we further pave the road for our highly distinguished Portfolio that already includes many high-value, complex and differentiated products.
